Chengdu Brilliant Pharmaceutical Co. Ltd. and ScinnoHub Pharmaceutical Co. Ltd. have jointly reported macrocyclic dual specificity protein kinase CLK2 and/or dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors.

Menin (MEN1)/MLL interaction inhibitors are reported in a Bala Therapeutics Inc. patent as potentially useful for the treatment of cancer and diabetes.

A Cytosite Biopharma Inc. patent describes prodrugs of granzyme B-targeting compounds reported to be useful as granzyme B-imaging agents for the diagnosis of cancer.

Vertex Pharmaceuticals Inc. has developed spirocyclic inhibitors of apolipoprotein L1 (APOL1) reported to be useful for the treatment of pancreatic cancer and focal segmental glomerulosclerosis.

Research at Humanwell Healthcare (Group) Co. Ltd. has led to the identification of interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Incyte Corp. has patented bicyclic amines acting as cyclin-dependent kinase 12 (CDK12) inhibitors and reported to be useful for the treatment of cancer.

A Shandong Luye Pharmaceutical Co. Ltd. patent discloses serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and viral infections.

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.

Etnova Therapeutics Co. Ltd. has described gadolinium complexes reported to be useful for the treatment of stroke, ataxia, epilepsy, spinal cord injury, optic nerve injury, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Yonsei University has divulged protein kinase inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.